Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 11/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22487886 | 0.94 | CNR2 (0.39) | CNR2ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL22375335 | 0.92 | CNR2 (0.38) | CNR2ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL25946278 | 0.87 | CCR1 (0.38) | ALDH1A1KDM4EGAAMAPTHPGD | |
| SCHEMBL17828092 | 0.83 | CCR1 (0.43) | ALDH1A1KDM4EGAAMAPTHPGD | |
| SCHEMBL20047718 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL20031198 | 0.81 | HPGD (0.35) | CNR2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL19464607 | 0.80 | KDM4E (0.47) | CNR2ALDH1A1KDM4EHPGDCNR1 | |
| SCHEMBL19425843 | 0.79 | CNR2 (0.36) | CNR2CNR1HTT | |
| SCHEMBL25086407 | 0.78 | CNR2 (0.39) | CNR2CNR1 | |
| SCHEMBL21719130 | 0.78 | KDM4E (0.31) | KDM4EMAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381144-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | SYNVENTA LLC (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381144-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | TRPV1, OPRL1, ADRA2C | CNR2 11/4885ALDH1A1 1427/4885KDM4E 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.